Synonym: (11β,16α)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
CAS Number: 83919-23-7
Empirical Formula (Hill Notation): C27H30Cl2O6
Molecular Weight: 521.43
MDL Number: MFCD00866003
Linear Formula: C27H30Cl2O6
Product Type: Chemical
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts M4074-5MG.
| assay |
≥98% (HPLC) |
| color |
white to off-white |
| form |
powder |
| InChI |
1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1 |
| InChI key |
WOFMFGQZHJDGCX-ZULDAHANSA-N |
| optical activity |
[α]/D +50 to +60°, c = 0.5 in methanol |
| originator |
Schering Plough |
| Quality Level |
100  |
| SMILES string |
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c5ccco5)C(=O)CCl |
| solubility |
DMSO: ≥20 mg/mL |
| storage temp. |
2-8°C |
| Application: |
Mometasone furoate has been used to study its effect on Leishmania major amastigotes. |
| Biochem/physiol Actions: |
Mometasone furoate is a 17-heterocyclic intranasal corticosteroid. It is effectively used as a first-line daily intranasal therapeutic for allergic rhinitis and nasal polyposis. Mometasone furoate is also used as an adjunct to anti-bacterials for treating acute rhinosinusitis. In addition, it relieves the symptoms of asthma in both adults and adolescents by exhibiting a broad spectrum of anti-inflammatory properties. |
| Biochem/physiol Actions: |
Mometasone furoate is an anti-inflammatory glucocorticoid. |
| Features and Benefits: |
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: |
This compound was developed by Schering Plough . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
51111800 |